# BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Issues Shareholder Letter Highlighting 2024 Milestones and 2025 Commercialization Goals

Nutriband (NASDAQ: NTRB) has released a shareholder letter from CEO Gareth Sheridan outlining key achievements in 2024 and plans for 2025, centered on advancing its AVERSA abuse-deterrent transdermal technology. The company is transitioning from feasibility to commercial development of AVERSA Fentanyl in partnership with Kindeva Drug Delivery, targeting a pivotal Human Abuse Liability clinical trial and NDA filing. AVERSA Fentanyl and AVERSA Buprenorphine could reach peak annual sales of up to $200 million and $130 million respectively. Nutriband also expanded its global patent portfolio to 46 countries and raised $8.4 million in a non-brokered placement. The company expects continued revenue growth in 2025 from its Pocono Pharma subsidiary, driven by its partnership with KT Tape.

 To view the full article, visit https://ibn.fm/NGtih

 About Nutriband Inc.

 Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information about the company, visit www.Nutriband.com.

 NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-nutriband-inc-nasdaq-ntrb-ceo-issues-shareholder-letter-highlighting-2024-milestones-and-2025-commercialization-goals/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nutriband-outlines-key-achievements-and-plans-for-2025-with-aversa-technology/5be4d149ebb390ac738e32c67eda1c38) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/254/30/airyUcmO.webp)